Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Advisory - Pharmascience Inc. recalls one lot of prescription antifungal drug PMS-Nystatin Oral Suspension: Product may pose a choking risk


OTTAWA, Jan. 17, 2020 /CNW/ -

Summary

Issue
Health Canada is advising Canadians that Pharmascience Inc. is recalling one lot of
PMS-Nystatin Oral Suspension, because it may contain clumps or jelly-like material that may pose a choking risk. Newborns, infants and people with difficulty swallowing are particularly at risk.

PMS-Nystatin Oral Suspension normally contains small visible particles and, as noted in the user instructions, it should be shaken well before each use to mix the drug evenly. For the affected lot, clumps greater than 1 millimetre (the size of a poppy seed) or jelly-like material may persist even after the product is shaken well.

Nystatin is a prescription antifungal drug for use by newborns, children and adults to treat and prevent fungal (candida) infections in the mouth, esophagus, stomach and intestinal tract.

Pharmascience Inc. notified Health Canada of this issue after receiving multiple complaints of clumps with the affected lot. Health Canada's laboratory testing of product samples also identified jelly-like material.

The affected lot was distributed throughout Canada starting in July 2019. To date, the company and Health Canada have not received any reports of adverse events involving this issue.

Who is affected
Consumers who have bought or who are using the affected product. Newborns, infants and people with difficulty swallowing are particularly at risk.

Affected products
PMS-Nystatin Oral Suspension 100,000 units/mL (DIN 00792667), Lot 681044, Expires 30-11-2021.

What consumers should do

What Health Canada is doing
Health Canada is monitoring the effectiveness of the company's recall and verifying that the company takes the necessary steps to prevent this issue from reoccurring. 

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 12:30
S2 Genomics, a manufacturer of automated tissue sample preparation systems, announced today at the Advances in Genome Biology and Technology (AGBT)?2020 meeting the launch of the Singulatortm 100 System. The Singulator 100 System automates the...

at 12:14
During the 5th annual St. Jude Spirit of the Dream, St. Jude Children's Research Hospital® honored Penny Hardaway with the Spirit of the Dream Award, which is presented to a person who embodies the mission of St. Jude and its founder, Danny Thomas....

at 10:04
PolyPid Ltd. today announced that it intends to confidentially submit a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the "SEC") relating to a potential initial public offering of its ordinary shares in the...

at 10:00
Spherix Incorporated today announced that on February 21, 2020, a special committee of the Board of Directors of Spherix Incorporated ("Spherix") approved a distribution to Spherix stockholders of 70,000 shares of Hoth Therapeutics, Inc. ("Hoth")...

at 09:10
Cred International Co., Ltd. has proudly announced that it is introducing the first Japanese Wellness Beauty Center called AN SPA NY in New York. This amazing new spa is located at a luxurious old Castle Hotel & Spa and will offer a wide range of...

at 03:00
World-renowned actor Laurence Fishburne (https://en.wikipedia.org/wiki/Laurence_Fishburne) is the host of the informational program "Behind The Scenes". The show features a wide array of subjects impacting people all around the world today. An...



News published on 17 january 2020 at 17:51 and distributed by: